{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:33:48Z","timestamp":1777937628791,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2015,5,15]],"date-time":"2015-05-15T00:00:00Z","timestamp":1431648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Scand J Public Health"],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:p>Aims: This population-based, retrospective study quantified the rates of all-cause and pneumococcal pneumonia, meningitis and septicemia in Norway from 2008 to 2009 and determined the proportions of cases caused by pneumococcal vaccine serotypes. Methods: Data on patients with all-cause and pneumococcal pneumonia, meningitis and septicemia were obtained from the Norwegian Patient Registry, which collects hospitalization data from all Norwegian public hospitals based on International Classification of Diseases codes. Norwegian Patient Registry case records linked to the Norwegian Surveillance System for Communicable Diseases provided serotype data for invasive pneumococcal disease in patients with microbiological cultures. Results: In 2008 and 2009, hospitalization rates were relatively stable for all-cause pneumonia (5.28 and 5.35, respectively, per 1000), meningitis (10.70 and 9.67, respectively, per 100,000), and septicemia (from 171.81 to 161.46 per 100,000). In contrast, rates decreased for International Classification of Diseases-10 diagnosed pneumococcal pneumonia (from 13.66 to 10.52 per 100,000), although these cases may be under-reported because of inclusion in all-cause pneumonia. Rates also decreased in diagnosed pneumococcal meningitis (from 1.60 to 1.19 per 100,000) and diagnosed pneumococcal septicemia (from 9.08 to 7.94 per 100,000). Diagnosed pneumococcal disease rates were highest in younger children and older adults, peaking at \u2a7e60 years old. Pneumococcal pneumonia, meningitis and septicemia caused by serotypes included in the 7-valent pneumococcal conjugate vaccine decreased substantially during the study period, with corresponding serotype replacement by non-7-valent pneumococcal conjugate vaccine serotypes. Conclusions: From 2008 to 2009, International Classification of Diseases-10 diagnosed pneumococcal pneumonia, meningitis and septicemia decreased in most age groups but remained greatest among subjects aged 0\u20131 and \u2a7e60 years.<\/jats:p>","DOI":"10.1177\/1403494815581695","type":"journal-article","created":{"date-parts":[[2015,5,15]],"date-time":"2015-05-15T22:46:14Z","timestamp":1431729974000},"page":"657-666","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical burden of pneumonia, meningitis and septicemia in Norway 2 years after 7-valent pneumococcal conjugate vaccine introduction"],"prefix":"10.1177","volume":"43","author":[{"given":"Samantha","family":"Munson","sequence":"first","affiliation":[{"name":"Pfizer Inc., USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireia","family":"Raluy-Callado","sequence":"additional","affiliation":[{"name":"Evidera, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitra","family":"Lambrelli","sequence":"additional","affiliation":[{"name":"Evidera, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radek","family":"Wasiak","sequence":"additional","affiliation":[{"name":"Evidera, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Evidera, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Gray","sequence":"additional","affiliation":[{"name":"Pfizer Inc., USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2015,5,15]]},"reference":[{"key":"bibr1-1403494815581695","first-page":"CD000422","author":"Moberley SA","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr2-1403494815581695","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268803001511"},{"key":"bibr3-1403494815581695","doi-asserted-by":"crossref","unstructured":"Bergsaker MR, Feiring B. Introduction of pneumococcal conjugate vaccine into the Norwegian childhood vaccination programme. Euro Surveill 11. http:\/\/www.eurosurveillance.org\/ViewArticle.aspx?ArticleId=2893. (2006, accessed 27 May 2013).","DOI":"10.2807\/esw.11.05.02893-en"},{"key":"bibr4-1403494815581695","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.03.087"},{"key":"bibr5-1403494815581695","unstructured":"National Patient Registry of Norway. http:\/\/www.npr.no (2012, accessed 31 January 2014)."},{"key":"bibr6-1403494815581695","unstructured":"Norwegian Institute of Public Health. Norhealth Population Composition. http:\/\/www.norgeshelsa.no\/norgeshelsa\/?language=en. (2014, accessed 2 March 2015)."},{"key":"bibr7-1403494815581695","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.01.127"},{"key":"bibr8-1403494815581695","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.13.1729"},{"key":"bibr9-1403494815581695","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.05.004"},{"key":"bibr10-1403494815581695","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072743"},{"key":"bibr11-1403494815581695","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.10.032"},{"key":"bibr12-1403494815581695","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu524"},{"key":"bibr13-1403494815581695","doi-asserted-by":"publisher","DOI":"10.3201\/eid1811.120329"},{"key":"bibr14-1403494815581695","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70090-1"},{"key":"bibr15-1403494815581695","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00137412"},{"key":"bibr16-1403494815581695","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00064-12"},{"key":"bibr17-1403494815581695","first-page":"233","volume":"16","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"CDC Pink Book"}],"container-title":["Scandinavian Journal of Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1403494815581695","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1403494815581695","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1403494815581695","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:11:33Z","timestamp":1777695093000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1403494815581695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,15]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.1177\/1403494815581695"],"URL":"https:\/\/doi.org\/10.1177\/1403494815581695","relation":{},"ISSN":["1403-4948","1651-1905"],"issn-type":[{"value":"1403-4948","type":"print"},{"value":"1651-1905","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,15]]}}}